Vericel (VCEL) Preferred Stock Liabilities (2012 - 2013)
Vericel (VCEL) reported Preferred Stock Liabilities of $42.9 million for Q2 2013, up 2856.97% on a YoY basis from $1.4 million in Q2 2012, and little changed sequentially from $42.9 million in Q1 2013.
Vericel (VCEL) Preferred Stock Liabilities (2012 - 2013) Analysis & Trends
Vericel (VCEL) has 2 years of Preferred Stock Liabilities data on file, last reported at $42.9 million in Q2 2013.
- For the quarter ending Q2 2013, Preferred Stock Liabilities rose 2856.97% year-over-year to $42.9 million; the trailing twelve-month figure through Jun 2013 stood at $42.9 million (up 2856.97% YoY), and the FY2012 full-year result was $41.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $42.9 million in Q2 2013, from $42.9 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $42.9 million in Q1 2013 to a low of $1.4 million in Q2 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Vericel | 2.30 Bn | 2.15 Bn | 49.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2013 | 42.88 Mn |
| Mar 31, 2013 | 42.88 Mn |
| Dec 31, 2012 | 41.61 Mn |
| Sep 30, 2012 | 40.36 Mn |
| Jun 30, 2012 | 1.45 Mn |